A multicenter Phase 2a clinical trial testing foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has begun dosing patients at Weill Cornell Medicine Multiple Sclerosis Center in New York. The Phase 2a study (NCT06292923) is assessing the safety and efficacy of Tiziana Life Sciences‘ therapy,…
foralumab nasal spray
A multicenter Phase 2a clinical trial testing Tiziana Life Sciences’ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has dosed the first patients enrolled at Yale MS Center. The Phase 2a study (NCT06292923) is assessing the treatment’s safety and efficacy against a placebo in…
Tiziana Life Sciences is partnering with a contract development and manufacturing organization with expertise in intranasal drugs to accelerate the development and commercial launch of foralumab, a treatment designed to be sprayed into the nose. Tiziana’s medication is being investigated in an expanded access program (EAP) and a…
Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded access program (EAP) experienced a lessening in fatigue levels after six months of treatment. That’s according to early findings from the EAP — a program that enables patients with serious…
Six of eight patients with nonactive secondary progressive multiple sclerosis (SPMS) being treated with foralumab nasal spray — all part of an intermediate-size expanded access program (EAP) allowing the therapy’s use — have experienced reductions in their fatigue levels. That’s according to treatment developer Tiziana Life Sciences,…
Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS). The trial will include about 54 participants, enrolled across six clinical sites. Patients will be randomly assigned to receive one of two…
Tiziana Life Sciences has dosed four new participants in an expanded access program investigating its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), the company announced. A total of 10 SPMS patients are now being followed outside of clinical trials in foralumab’s expanded…
Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six people with nonactive secondary progressive multiple sclerosis (SPMS) involved in an expanded access program. Microglia are resident immune cells in the brain believed to play a role in driving…
Tiziana Life Sciences plans to launch a Phase 2 clinical trial to investigate its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) in late 2023, the company announced. The decision follows a Type C meeting with the U.S. Food and Drug Administration (FDA), wherein…
A second person with non-active secondary progressive multiple sclerosis (SPMS) treated with foralumab nasal spray in a single-patient access program is continuing to show improvements 11 months after starting the therapy, according to an update from foralumab’s developer, Tiziana Life Sciences. The patient, dubbed EA2, experienced a…